Jeff Yass’s Cellectar Biosciences CLRB Stock Holding History

Jeff Yass’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-820	Closed	-$61.5K	–	12094
2024 Q2	$61.5K	Buy	820 +240	+41%	+$23K	﹤0.01%	11323
2024 Q1	$69.3K	Buy	+580	New	+$62.9K	﹤0.01%	11416

Other funds holding CLRB

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RCA

Riverview Capital Advisers Boston, Massachusetts $349M AUM 33.11% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Jeff Yass's CLRB Position: Q1 2026 in Review

Jeff Yass sold out of Cellectar Biosciences (CLRB) in Q1 2026, closing a stake of 12,204 shares — an estimated $36K sold.

Jeff Yass first reported a position in CLRB in Q4 2016 and held it in 9 quarters. The position peaked at $678K in Q4 2017. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2026.

Jeff Yass reported no remaining Cellectar Biosciences position as of Q1 2026 after selling out during the quarter.
Jeff Yass sold 12,204 Cellectar Biosciences shares in Q1 2026, an estimated $36K.
Jeff Yass first reported a position in Cellectar Biosciences in Q4 2016 and held it in 9 quarters.
Jeff Yass's Cellectar Biosciences position peaked at $678K in Q4 2017.
19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.